Ver vídeos

What is Skilarence?

Your doctor has prescribed Skilarence for the treatment of your psoriasis. This material provides you with information to guide you during your treatment.

It is a tablet for the treatment of moderate-to-severe plaque psoriasis in adults in need of systemic medicinal therapy. Your healthcare professional will have decided with you, that this is the right medicine for condition, before prescribing it for you.
It contains the active ingredient dimethyl fumarate.

Dimethyl fumarate is a type of medicine called fumaric acid ester: this type of medicine has been used in the treatment of psoriasis for over 20 years.

Dimethyl fumarate works on some of the cells of the immune system (the body’s natural defences). It affects the activity of some of the immune system and reduces the production of some of the substances involved in causing psoriasis.

The tablets are designed to reduced stomach irritation by having a special ‘gastro-resistant’ coating. There are two different tablets strengths available:

Skilarence 30 mg

42 tablets

These 30 mg tablets are used during the initial period of the treatment to help find the optimal dose according to your needs, as well as to minimise stomach problems or other side effects.

Skilarence 120 mg

90 or 180 tablets

These 120 mg tablets are used as the dose is increased (dose adjustment) and during maintenance treatment.

Report adverse event

This website provides information to guide you during treatment with Skilarence. Please refer to the Patient Information Leaflet contained within your medicine pack for further information.

If you get any side effects, talk to your healthcare professional, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ (for United Kingdom) or by contacting the HPRA (for Ireland) at: Website: www.hpra.ie, e-mail: medsafety@hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine. Adverse events should also be reported to Almirall Ltd. IE Tel: +353 (0)14319836; UK Tel: 0800 0087 399; Email: Almirall@EU.ProPharmaGroup.com

Please read our Drug Safety Privacy Policy where you will find details of how we handle the processing of personal information when dealing with your adverse event report.

This website is intended only for patients taking Skilarence® (dimethyl fumarate) to help them maximise their treatment’s benefits. Please refer to the Patient Information Leaflet contained within the medicine pack for further information.


If you get any side effects, talk to your healthcare professional, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk/ (for United Kingdom) or by contacting the HPRA (for Ireland) at: Website: www.hpra.ie, e-mail: medsafety@hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.

By reporting side effects you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Almirall Ltd. IE Tel: +353 (0)14319836; UK Tel: 0800 0087 399; Email: Almirall@EU.ProPharmaGroup.com